Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron
CEO, Mike Lampron
Source: Mach7 Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mach7 Technologies (M7T) has signed a seven-year contract with leading U.S. health care company Trinity Health
  • The $5.26 million contract will see Mach7 supply Trinity with the license for its eUnity diagnostic enterprise viewer, as well as associated support services
  • The company expects its eUnity viewer to be installed in multiple facilities within Trinity’s network of 92 hospitals
  • Mach7 also believes revenue from this new deal will begin flowing by the end of the financial year, once the first licence orders are made
  • M7T’s shares have opened trading up 4.08 per cent for $1.02 per share

Mach7 Technologies (M7T) has signed a new seven-year contract with leading U.S. catholic health care company Trinity Health.

As part of the contract, Mach7 will supply Trinity with the license for its eUnity diagnostic enterprise viewer, as well as associated support services.

In return, Trinity will pay the company $5.26 million in licence, support and maintenance fees.

Today’s announcement is a significant deal for Mach7, as it gives it access to Trinity’s huge network of 92 hospitals and 100 continuing care locations across 22 states.

Speaking on the new contract, Mach7 Technologies CEO Mike Lampron said the deal was also the company’s first big signing since acquiring Client Outlook.

“[This contract] highlights our investment thesis around the importance of a world-class Enterprise Viewer to an Enterprise Imaging Strategy,” Mike said.

“This announcement represents a launching point for a larger and more integrated relationship with Trinity involving our vendor-neutral archive and diagnostic viewing solutions,” he added.

M7T expects revenue from the new deal to begin flowing by the end of the financial year, once the first licence orders have been received.

Shares in Mach7 Technologies have opened the final trading session of the week up 4.08 per cent at $1.02 per share.

M7T by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…